about
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: a pilot studyDiagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagusFDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal-gastric junction.MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma.Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiencyConcurrent chemoradiotherapy in locally advanced non-small cell lung cancer—Prognostic factors and reasons for treatment failure in group of patients 1996–2008The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer
P50
Q31122505-CE7A7DBE-D697-4460-B0BE-D076A336010BQ33349587-36AC2D79-6847-4188-A8C6-3AB26E25BFF8Q33384947-825142B5-DFDC-4798-AD8B-4F5672F7B07AQ34584928-E81ACB79-BAF7-4832-93BA-EFB41FF1C14AQ35545218-C49142AD-AE6C-40AB-8926-A8E7650D9AB0Q37329672-37014FFB-2BB0-47B5-BA02-E5B379C8CFBDQ38808371-AE492FB3-3A18-4AE3-BE42-21478B778342Q40127912-45EA0C67-AA09-4BAB-8790-C3E03A8C8FA5Q45056439-3C3DAEBC-A35E-4C0C-936E-9EFCB5A091DCQ47346374-DFC0681B-D807-40AA-B110-11622F8E24E4Q48439220-45A738E1-0CD7-4847-92C9-C5A3851A727DQ54368657-365F750E-49FC-4668-99B0-62852EE4B0A6Q59384038-7029E474-6C86-4159-AEB4-1240F68BCADFQ59384058-77D8963F-7A92-4340-AF29-EDC7E7FC295EQ59384061-2337555B-455C-45E9-9AE8-19775FF2555BQ59384124-0E146F25-0F0B-48AF-9600-6E7C06EAB333
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Milada Zemanova
@ast
Milada Zemanova
@en
Milada Zemanova
@es
Milada Zemanova
@sl
Milada Zemanová
@cs
type
label
Milada Zemanova
@ast
Milada Zemanova
@en
Milada Zemanova
@es
Milada Zemanova
@sl
Milada Zemanová
@cs
altLabel
M Zemanova
@en
Milada Zemanová
@en
Zemanova M
@en
Zemanova Milada
@en
prefLabel
Milada Zemanova
@ast
Milada Zemanova
@en
Milada Zemanova
@es
Milada Zemanova
@sl
Milada Zemanová
@cs
P214
P1053
M-1921-2017
P106
P108
P1153
6602889964
P21
P214
P31
P3829
P496
0000-0002-1904-1035